l-threo-dihydroxyphenylserine (l-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: A multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure
- 384 Downloads
This study was designed to determine the efficacy and tolerability of increasing doses ofl-threo-dihydroxyphenylserine (l-threo-DOPS) in treating symptomatic orthostatic hypotension associated with multiple system atrophy (MSA) and pure autonomic failure (PAF). Following a one-week run-in, patients (26 MSA; 6 PAF) with symptomatic orthostatic hypotension received increasing doses ofl-threo-DOPS (100, 200 and 300 mg, twice daily) in an open, dose-ranging study. Incremental dose adjustment (after weeks two and four of outpatient treatment) was based on clinical need until blood pressure (BP), and symptoms improved. Final dosage was maintained for six weeks. Withl-threo-DOPS, systolic BP decrease was reduced during orthostatic challenge (−22±28 mm Hg reduction from a baseline decrease of 54.3±27.7 mm Hg, p=0.0001, n=32; supine systolic BP at final visit was 118.9±28.2 mm Hg). By the end of the study, 25 patients (78%) improved, and in 14 patients (44%) orthostatic hypotension was no longer observed. Decreased orthostatic systolic BP decrease occurred in 22% (7/32), 24% (6/25) and 61% (11/18) of patients treated with 100, 200, and 300 mgl-threo-DOPS twice daily, respectively. An improvement occurred in symptoms associated with orthostatic hypotension, such as light-headedness, dizziness (p=0.0125), and blurred vision (p=0.0290).l-threo-DOPS was well tolerated, with the 2 serious adverse events reported being a possible complication of the disease under study, and with no reports of supine hypertension. I conclusion,l-threo-DOPS (100, 200, and 300 mg, twice daily) was well tolerated. The dosage of 300 mg twice dailyl-threo-DOPS seemed to offer the most effective control of symptomatic orthostatic hypotension in MSA and PAF.
Key wordsl-threo-DOPS neurogenic orthostatic hypotension multiple system atrophy (MSA, Shy-Drager syndrome) pure autonomic failure (PAF)
Unable to display preview. Download preview PDF.
- 1.Mathias CJ. Disorders of the autonomic nervous system. In:Neurology in clinical practice. 3rd ed. Bradley WG, Daroff RB, Fenichel GM, et al., eds. Boston: Butterworth Heinemann; 2000. pp. 2131–2165.Google Scholar
- 5.Mathias CJ and Bannister R. Dopamine beta-hydroxylase deficiency. InAutonomic failure. A textbook of clinical disorders of the autonomic nervous system, 4th ed. Mathias CJ, Bannister R, eds. Oxford and New York: Oxford University Press; 1999. pp. 387–401.Google Scholar
- 6.Suzuki T, Azuma T, Araki S, et al. Treatment of autonomic dysfunction with L-threo-3-4-dihydroxyphenylserine (L-DOPS) in patients with familial amyloidotic polyneuropathy: A multicentre study. In:Amyloid and amyloidosis. Isobe T, Araki S, Uchino F, et al., eds. New York and London: Plenum Press; 1988. pp. 851–856.Google Scholar
- 8.Sobue I, Senda Y, Hirayama K, et al. Clinical pharmacological evaluation of L-threo-3-4-dihydroxyphenylserine (L-DOPS) in Shy-Drager's syndrome and its related diseases. A nation-wide double-blind comparative study.Jpn J Clin Exp Med 1987; 141:353–378.Google Scholar
- 10.Narabayashi H, Nakanishi T. Therapeutic effects of L-DOPS in Parkinson's disease, double-blind comparative study against placebo as control in patients with long-term levodopa therapy.Clin Eval 1987; 15:423–457.Google Scholar
- 13.Committee for Proprietary Medicinal Products. Points to consider on missing data.CPMP/EWP/1776/99 draft. London, January 25, 2001.Google Scholar
- 16.Mathias CJ. Autonomic disorders and their recognition.N Engl J Med 1997; 10:721–724.Google Scholar